|
|
September 11, 2002 Scientists at NSLS discover how papillomavirus ‘unzips’ DNAFinding may lead to drugs to prevent sexually transmitted disease and cervical cancerInfection with the human papillomavirus (HPV) is the most common sexually transmitted disease in the U.S. According to the Centers for Disease Control and Prevention in Atlanta, Georgia, an estimated 20 million Americans are currently infected – but the vast majority does not know it. Though HPV sometimes causes genital warts, in most cases, it infects people without causing visible symptoms. Women with persistent infections from certain types of HPV are at risk for cervical cancer, as 99 percent of cervical cancers around the world are associated with HPV infection.
“We know very little about how papillomavirus replicates,” says biologist Leemor Joshua-Tor, the Cold Spring Harbor team leader. “So we decided to look at the molecular details of how the replication mechanism is initiated, with the aim of helping to design drugs that act like monkey wrenches in the replication process.” Like all viruses, a papillomavirus is an infectious agent that uses the cells it infects to reproduce itself. Replication of HPV does not kill the host cells, but can make them cancerous.
“The DNA double helix can be replicated only if it is ‘unzipped,’ which allows proteins called DNA polymerases to make copies of each strand,” Joshua-Tor explains. “The E1 protein is known to initiate the ‘unzipping’ process, but how it does it is not very well understood.” To look carefully at how E1 proteins attach to viral DNA, Joshua-Tor
and her postdoctoral associate, Eric Enemark, in collaboration with
Arne Stenlund, a renowned papillomavirus expert at CSHL, grew
crystals of E1 and papillomavirus DNA at two different stages of the
attachment process, in which either two or four E1 proteins bind to
DNA.
The researchers then used a technique called x-ray crystallography to determine the positions of the atoms making up the E1 proteins and DNA. X-rays produced by the NSLS were projected toward the crystals, and the positions of the atoms were determined by looking at how the x-rays scattered off the crystal. To their surprise, Joshua-Tor and her colleagues observed that E1 uses two separate modules, one shaped like a loop and the other like a helix, to bind DNA, each one binding to a different DNA strand (Figure 1). “This is very unusual,” Joshua-Tor says. “We expected that both modules would bind the two strands simultaneously.” The scientists also noticed that the loop bind more tightly than the helix, giving loops a larger role in E1-DNA binding than helices. When two E1 proteins attach the DNA, Joshua-Tor and her collaborators observed that the loops bind different strands (Figure 1). When four proteins bind to DNA, they form two pairs facing each other, with proteins in each pair binding the same DNA strand as the ones on the opposite side (Figure 2).
Joshua-Tor and her colleagues suggest that the four proteins separate into two pairs, each recruiting four additional E1 proteins, thus creating two hexamers that would move in opposite directions (Figure 3). Each hexamer would encircle either strand, and act like a little propeller that rotates around the strand, thus ‘unzipping’ it from its partner DNA strand along the way. “If this is the way these proteins operate, it is pretty clever,” Joshua-Tor says. “This is the first time that it has been found that the two individual DNA strands bind to two separate protein modules prior to the DNA ‘unzipping’ process.” While Joshua-Tor and her colleagues are still investigating the papillomavirus-induced DNA replication, they are also starting to test compounds that interfere with papillomavirus DNA replication. For example, Anitra Auster, a graduate student, is developing compounds that could interfere with the DNA replication induced by a high-risk type of human papillomavirus that can lead to cervical cancer. “Understanding these binding mechanisms could significantly improve the treatment of this sexually transmitted disease,” Joshua-Tor says. “We can now design and test drugs aiming to prevent E1 proteins from attaching to the viral DNA, which is one of the first steps to making much-needed antivirals against HPV infections and HPV-induced cervical cancer.” BEAMLINE PUBLICATION FOR MORE INFORMATION SCIENCE WRITER: Patrice Pages |